ARTICLE | Clinical News
Novo Nordisk begins diabetes Phase III
November 6, 2001 8:00 AM UTC
NVO started a Phase III trial of DR-2725 (NN622) peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist to treat Type II diabetes. The trial start triggers a milestone to Dr. Reddy'...